Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab, erlotinib, and sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with erlotinib is more effective than giving sorafenib in treating patients with liver cancer.
This randomized phase II trial is studying how well giving bevacizumab together with erlotinib works compared with sorafenib as first-line therapy in treating patients with advanced liver cancer.
This study is being done to find out if adding trastuzumab to breast radiation therapy will be more effective than breast radiation therapy alone in preventing the occurrence of breast cancer in the same breast, in the other breast, or in other parts of the body.
Trastuzumab is called a targeted therapy because it targets breast cancers that make too much of a protein called HER2. Too much of the HER2 protein can cause cells to receive extra growth signals. Trastuzumab has been shown to block the HER2 protein and to slow down or stop the growth of HER2+ invasive breast cancers.
Patients will be randomized into one of two treatment groups. One group will receive radiation only, and the other group will receive Trastuzumab plus radiation therapy.
The goal of this study is to improve the chances that your tumor shrink and even disappear by adding a special drug to routine chemotherapy and radiation before surgery. This drug, named panitumumab, blocks a target at the molecular level that when "turned on" causes reactions that make your tumor grow and spread.
Patients participating in this study will receive panitumumab in combination with two other chemotherapy drugs called cisplatin and docetaxel every 2 weeks for 10 weeks. Patients will also receive radiation therapy at the same time as the chemotherapy starting on week 5. Patients will also receive other tests and procedures that are part of regular cancer care.
This study is for patients who have had surgery for extrahepatic cholangiocarcinoma (cancer of the bile duct or gallbladder).
The purpose of this study is to find out what effects, good and/or bad, capecitabine, gemcitabine, and radiation have on you and your cholangiocarcinoma. Capecitabine has been FDA approved for treatment of colon cancer and breast cancer. Gemcitabine has been FDA approved for treatment of pancreas cancer, lung cancer, and breast cancer.
If you participate in the study, you will receive capecitabine and gemcitabine for four cycles. About a week after you have finished those four cycles, you will begin radiation treatment. You will receive radiation 5 days a week for 5-6 days.
The purpose of this study is to find out what effects (good and/or bad) chemotherapy combined with external radiation therapy and possible removal of your bladder has on you and your cancer. The chemotherapy drugs used in this study (5-Fluorouracil, cisplatin, and gemcitabine) are not experimental drugs. This research is being done because we do not know whether one combination of drugs with radiation is superior to another in the treatment of your disease. This study uses similar therapies to the standard treatment, but chemotherapy and radiation therapy are given before removal of the bladder is considered. In this study, bladder removal is advised if, after chemotherapy and radiation, your tumor has not completely disappeared, if your tumor comes back, or if it gets larger.
Patients who participate in this trial will be randomized into two groups. Patients will receive either cisplatin and 5-FU chemotherapy and radiation twice per day OR gemcitabine chemotherapy and radiation once per day. Participation in this study may last up to 8 months with continued follow up after treatment is complete.
This study is for patients with metastatic clear cell renal cell carcinoma. The purpose of this trial is to describe the gene expression of VEGF and non-VEGF angiogenic (the formation of new blood vessels) growth factor genes in kidney cancer specimens from patients with metastatic kidney cancer treated with sunitinib maleate (Sutent). Sutent® (sunitinib) is a drug that is designed to block tumor cell growth in several ways. Sunitinib targets several enzymes (proteins by your body that help cells interact with one another) on blood vessel cells and tumor cells. Several of these targets are thought to be involved in angiogenesis (making of blood vessels). Sunitinib is approved by the FDA for the treatment of advanced renal cell cancer. As a part of this study, you will have a nephrectomy (surgery to remove a kidney or part of a kidney) after your treatment with Sunitinib. Researchers are not certain what effects nephrectomies alone have on your disease. Some studies, as well as standard practice, suggest value in giving drug therapy treatment before performing nephrectomies. Therefore, in this study your surgery will be delayed until after you have been treated with Sunitinib. You will be asked to consent to provide some of your tissue from this surgery to help researchers identify tumor cells that influence growth of vascular endothelial growth factor (VEGF), a protein that is a major factor in promoting the growth of new blood vessels, and to find out more information about Sunitinib’s role in hindering this relationship. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery. This clinical trial is studying how well sunitinib works when given before and after surgery in treating patients with metastatic kidney cancer that can be removed by surgery. Treatment on this trial may last up to 18 months.
The purpose of this trial is to test the experimental drug combination of pemetrexed and cisplatin, given with radiation. This study is testing whether this experimental combination of drugs combined with radiation will prove to be more effective in eliminating non-small cell lung cancer without increasing side effects.
Patients who participate in this study will be randomly assigned to one of two treatment groups. Patients in the first group will receive pemetrexed + cisplatin + radiation therapy. Patients in the second group will receive etoposide + cisplatin + radiation therapy. All chemotherapy is given intravenously.
The purpose of this study is to determine if adding bevacizumab to the current standard chemotherapy, namely doxorubicin, cyclophosphamide, and paclitaxel, reduces the risk of recurrence compared to standard chemotherapy alone.
Patients are stratified according to planned dose schedule of doxorubicin and cyclophosphamide. Patients are further stratified according to estrogen receptor status, lymph node involvement, and received/planned radiation and surgery treatment. Patients are randomized to 1 of 3 treatment arms in which they will receive either paclitaxel, placebo, bevacizumab, or a combination of two of these drugs.
In all arms, treatment continues in the absence of disease progression or unacceptable toxicity.
Have you been in a combat situation since 1980 and suffering from flashbacks, anxiety, poor sleep and isolation from others? If so, we are conducting a 14 week trial to determine the efficacy of a new medication called Nepicastat versus placebo in the treatment of PTSD in combat Veterans who have served since 1980 who are between the ages of 18 and 65.